Archive · 31 Jul 2026
Sun Pharma Q1 Profit Up 27%, India Formulations Grow 16%
Sun Pharma is a big drug company in India.
In the first part of its 2027 financial year, it made more money than last year – about 27% more.
Its sales went up too, especially in India where it sold 16% more medicines.
The company also said it is still working on buying another company called Organon, and the deal should finish in early 2027.
The CEO said the good results came from strong sales in India and new medicines sold in the U.S. and other countries.
Net profit Q1FY27 rose 27% YoY to Rs 2,894.79 crore.
Revenue increased 10.46% YoY to Rs 15,299.88 crore.
India formulations business grew 16% YoY to Rs 5,475 crore, 36.1% of sales.
EBITDA margin 28.9%, adjusted net profit Rs 3,089 crore.
Organon acquisition remains on track for early 2027 after shareholder approval.
- Who
- Sun Pharma
- What
- Q1FY27 financial results and progress on Organon acquisition
- When
- First quarter of fiscal year 2027
- Where
- India
- Why
- Strong performance driven by India business and innovative medicines
- Net profit Q1FY27
- Rs 2,894.79 crore
- Revenue Q1FY27
- Rs 15,299.88 crore
- India formulations growth
- 16% YoY to Rs 5,475 crore
- EBITDA margin
- 28.9%
- Organon acquisition status
- On track for early 2027 after shareholder approval